噻托溴铵联合茚达特罗治疗慢性阻塞性肺疾病的临床效果以及肺功能指标观察

Clinical effect and pulmonary function of tiotropium combined with indacaterol in the treatment of chronic obstructive pulmonary disease

目的探究噻托溴铵联合茚达特罗治疗慢性阻塞性肺疾病的临床效果。方法选择慢性阻塞性肺疾病患者为研究对象,70例患者均为2021年2月-2022年2月收治病例。按随机数字表法分成对照组(噻托溴铵)和试验组(噻托溴铵+茚达特罗),每组35例患者。比较疗效、肺功能、炎症因子、药物不良反应。结果疗效比较,试验组97.14%高于对照组的80.00%,差异有统计学意义(P<0.05)。治疗前,两组肺功能指标FVC、PEF、FEV1、FEV1/FVC进行比较,差异无统计学意义(P>0.05)。治疗后,上述指标与治疗前相比均提升(P<0.05)。治疗后,试验组与对照组肺功能指标比较,试验组指标水平更高(P<0.05)。两组患者治疗前hs-CRP、IL-6、TNF-α指标比较,差异无统计学意义(P>0.05)。治疗后,两组患者hs-CRP、IL-6、TNF-α水平与治疗前相比均明显降低(P<0.05)。试验组治疗后与同期对照组比较,hs-CRP、IL-6、TNF-α水平均更低(P<0.05)。试验组药物不良反应发生率与对照组比较,差异不显著,P>0.05。结论在慢性阻塞性肺疾病治疗中联合使用噻托溴铵与茚达特罗效果确切,应推广使用。

Objective To explore the clinical effect of tiotropium bromide combined with indacaterol in the treatment of chronic obstructive pulmonary disease.Methods Patients with chronic obstructive pulmonary disease were selected as the research objects,and 70 patients were selected from February 2021 to February 2022.According to the random number table method,they were divided into control group(tiotropium bromide)and experimental group(tiotropium bromide+indacaterol),with 35 patients in each group.The efficacy,pulmonary function,inflammatory factors and adverse drug reactions were compared.Results The efficacy of experimental group was 97.14%higher than that of control group(80.00%),and the difference was statistically significant(P<0.05).There were no significant differences in FVC,PEF,FEV1 and FEV1/FVC pulmonary function indexes between the two groups before treatment(P>0.05).After treatment,the above indexes were increased compared with those before treatment(P<0.05).Compared with the control group,the pulmonary function index level of the experimental group was higher after treatment(P<0.05).There were no significant differences in hs-CRP,IL-6 and TNF-αindexes between the two groups before treatment(P>0.05).After treatment,the levels of hs-CRP,IL-6 and TNF-αwere significantly decreased compared with those before treatment(P<0.05).Compared with the control group,the levels of hs-CRP,IL-6 and TNF-αin the experimental group were lower after treatment(P<0.05).The incidence of adverse drug reactions in experimental group was compared with that in control group,P>0.05.Conclusion The combined use of tiotropium and indacaterol in the treatment of chronic obstructive pulmonary disease is effective and should be popularized.